Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. Here, HDAC9 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.